Auxesis Pharma is a Swedish pharmaceutical company developing innovative medicines for localized pain and irritation in the skin — for both humans and animals.
Our pharmaceutical development in Sweden is built on proprietary patents, long-term research, and a clear vision: to redefine the therapeutic category of “pain and irritation in the skin” with science at its core.
Auxesis Pharma is a pharmaceutical company determined to change how pain and irritation in the skin are treated. With science as our foundation and a breakthrough patent, we develop innovative medicines that can rapidly relieve and remove skin pain — in formats that are easy to use for both consumers and professionals.
What began as a research project has evolved into a Swedish pharmaceutical group with proprietary patents, established production, and a growing portfolio of medicines for both humans and animals.
We focus on the category of localized pain and irritation in the skin, where the need for effective and accessible treatments is significant — in both human and veterinary medicine.
More about us
Parent company and central securities register company that holds the rights to the Group’s patents in selected medical research areas. The focus is to develop innovative medicines for localized pain and irritation in the skin — for both humans and animals.
Subsidiary founded in 2024. The company is responsible for prototype manufacturing and will hold a license to produce and market our medical products in the Nordic region, as well as manage licenses for the rest of the world. A dedicated factory will be established in the future to ensure quality, traceability, and efficient deliveries.
Subsidiary focused on the animal care market, primarily dogs and livestock. Here we develop topical solutions for skin pain and irritation in animals, with the aim of reducing suffering and the need for systemic medications.
This means we aim to:
This vision shapes everything from our patent strategy and product development to how we approach manufacturing and choose partnerships.
This means we focus on:
Our mission ensures we take innovation all the way from the laboratory to a finished product — with quality and evidence at the core.
Behind Auxesis is a cross-functional team with experience from pharmaceutical development, research, entrepreneurship, and industry.
Together, we move Auxesis from scientific results to finished products on the market — with science, quality, and real-world impact at the core.
Founder and Board Member
Roar Adelsten is the founder of Auxesis Pharma Holding AB, Auxesis MedTech AB, and Auxesis Animal Care AB.
He has nearly 30 years of experience in the pharmaceutical industry as CEO, Field Manager, and medical consultant — including at Pfizer AS in Norway — and has worked in Sweden, Norway, and the US within reconstructive orthopedic surgery, orthopedics, surgical instruments, and joint and bone arthroplasty.
Medical Science, Toxicologist, IHM Business School
Peter Åberg is CEO and business advisor and is part of the ASA.P pharmaceutical development team.
He has more than 20 years of experience as a leader and organizational developer within medtech, pharmaceuticals, and manufacturing, including roles as CEO and Sustainability Director.
Peter has an academic background in toxicology, serves as a UN representative, and works with international sustainability standards for leadership, environment, and business development.
CFO
Lars Larsson is CFO and business advisor focused on finance, funding, and management.
He has nearly 20 years of experience as a management consultant and has worked with business development and finance in senior roles within IT, telecom, and real estate — including as Global Delivery Manager at Telia. Lars holds a BSc in Public Affairs and an MSc in Management.
Chairman
Magnus Larsson is Chairman and an economist from Stockholm University with a focus on accounting and finance. He has founded several companies and held senior leadership roles in the IT industry since the 1980s.
Magnus has served as Group CEO and Chairman in both listed and private companies, worked as a consultant in financial governance, and held several trusted positions within the Confederation of Swedish Enterprise.
Intellectual Property, Commercial Agreements & Dispute Resolution
Peter Hedberg works with intellectual property, commercial agreements, and dispute resolution. He is an expert in IP law, marketing, and commercial law with extensive experience in strategic advisory.
He has supported Swedish and international companies with IP strategies, infringement matters, and commercial issues and is a valued advisor in complex business contexts.
Board Member, Sales and Marketing
Charlotta Larsson is a Board Member and business advisor focused on sales and marketing. She is a strategy expert within FMCG and OTC with more than 25 years of international experience from multinational companies.
Charlotta has led global teams, developed brand strategies, and built investor-backed growth companies. She holds an MSc in Business Administration from the School of Business, Economics and Law at the University of Gothenburg.
Board Member
Rune Nordström is a Board Member of Auxesis and an experienced entrepreneur within corporate governance, leadership, marketing, and communication.
He has held senior roles as a director within the public sector, including in the predecessor organization to SKR, and served as Head of Information at the National Institute for Working Life.
Project Manager, CoxyPet
Robert Lind is a project manager with a background in political science, law, psychology, and sociology. He holds Swedish fil.mag. degrees in both political science/law and psychology/sociology.
He has worked within the Scania Group on project management and international customer collaborations and has also held assignments within national radio and TV stations in Poland.
Web Developer & IT Management Support
Helena Adelsten works as a web developer and management support professional with an academic background in IT and economics, as well as experience in entrepreneurship and technical development.
She designs and builds digital solutions with high technical precision, optimizes performance, and turns complex needs into robust systems. With a focus on quality, user experience, and sustainable technology, she delivers tailored and innovative solutions.
Clinical Trial Consultants
Board Member
Helena Litorp (MD, PhD) is Chief Medical Officer and a specialist physician in obstetrics and gynecology.
She is an associate professor in global health with more than 15 years of experience in clinical practice, education, and international research.
RegSmart Life Science
MSci Pharm and PhD
Agneta Larhed has served as regulatory advisor to Auxesis since August 2024, with a primary focus on pharmaceutical quality and regulatory requirements in clinical development.
Her work includes quality requirements for both active pharmaceutical ingredients and finished medicinal products prior to clinical trials and marketing authorization applications.
Agneta has previously held senior positions within research and development, formulation development, and regulatory authorities, working with quality systems and approval processes for medicinal products.
RegSmart / Zelmic
MSc Chem Eng and PM
Susanna Liljedahl has been part of the ASA.P pharmaceutical development team since September 2024, responsible for formulation development and manufacturing of the Investigational Medicinal Product (IMP).
She is a Project Manager at Zelmic and brings more than ten years of experience as a researcher and project leader, including roles at AstraZeneca, with a focus on formulation and process development of pharmaceuticals.
Susanna has served on leadership teams and driven product and process development across multiple companies, with strong expertise in scalable development and quality-driven manufacturing.
Zelmic
CMO
Marie Gårdmark (MSc Pharm, PhD) has served as regulatory advisor to Auxesis since August 2024, focusing on preclinical and clinical development.
She has extensive experience from senior roles within regulatory authorities and research and development, with particular expertise in global regulatory strategies, due diligence processes, and scientific advice meetings in both the EU and the United States.
Marie has worked broadly within clinical and preclinical research, primarily in early-stage pharmaceutical development and strategic development planning.
Zelmic develops topical and transdermal pharmaceutical formulations and supports Auxesis in formulation development. They are an experienced, privately owned CRO and CDMO.
To ZelmicAFRY supports Auxesis in planning and designing a sustainable production model. AFRY assists with medical research, regulatory interactions with the Swedish Medical Products Agency, and the establishment of the production facility in Östersund.
To AFRYAuxesis collaborates with EIP on patents for ASA.P® and forthcoming patent applications. EIP has broad international expertise in drafting strong patent applications worldwide.
To EIPClinical Trial Consultants (CTC) is a specialized consultancy in clinical development, supporting pharmaceutical and medtech companies throughout the clinical process. With deep medical and regulatory expertise, CTC contributes to efficient study design, execution, and quality assurance across early and late clinical phases.
To CTCAuxesis uses Edlund & Partners as its audit firm. Edlund & Partners has the competence, experience, and authorization to support companies in connection with stock exchange listings.
To EdlundRegSmart Life Science AB supports Auxesis with regulatory matters related to the commercialization of ASA.P®. They help navigate a complex and evolving regulatory landscape.
To RegSmartIQVIA and Svensk Läkemedelsstatistik provide accurate and comprehensive analyses of the pharmaceutical industry in Sweden and globally. Through thorough analysis and tailored consulting services, Auxesis gains valuable insights for decision-making.
To IQVIARamberg Advokater in Stockholm is a full-service law firm with specialist expertise across multiple practice areas. Ramberg provides legal support to Auxesis, including commercial law, trademark matters, and a wide range of regulatory legal issues worldwide.
To RAMBERG
